DG
Highly rated in
19
conditions

Dr. David E. Gerber

University Hospital Medical Oncology Clinic - Lung At Seay Biomedical Building
Dallas, TX
Highly rated in
19
conditions
Specialties:Hematology Oncology | Oncology
Experience:23 Years
Clinical Trials:Currently Recruiting for 8 Trials
Accepts:New PatientsMedicare
Highly rated in
19
conditions
About|Expertise|Insurance|Location|Research
Areas of Expertise

Many doctors have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a doctor treats and their level of experience.

Check Dr. David E. Gerber's experience treating your condition:
About Dr. David E. Gerber

David Gerber is a Hematologist Oncology specialist and an Oncologist in Dallas, Texas. Gerber has been practicing medicine for over 23 years and is highly rated in 19 conditions, according to our data. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NCSLC), EGFR Positive Lung Cancer, Gamma Knife Radiosurgery, and Bone Marrow Transplant. He is licensed to treat patients in Texas. Gerber is currently accepting new patients.

His clinical research consists of co-authoring 231 peer reviewed articles and participating in 26 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. David E. Gerber it is best to call his office and ask if your insurance is accepted.

Accepts Medicare

Dr. David E. Gerber accepts the following insurance:

  •  Ambetter
Call to see if your plan is accepted.
Locations
2201 Inwood Rd, Dallas, TX 75235
Background & Education
Graduate Institution
Js Weill Medical College, Cornell University, 2000
Specialties
Hematology Oncology
Oncology
Licenses
Internal Medicine in TX
Hospital Affiliations
Parkland Health And Hospital System
William P Clements Jr University Hospital
Languages Spoken
English
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

25 Clinical Trials
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Enrollment Status: Recruiting
Publish Date: December 14, 2022
Intervention Type: Other, Drug, Biological
Study Drugs: CarboplatinCisplatinGemcitabine HydrochloridePaclitaxelPembrolizumabPemetrexed Disodium
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Recruiting
Publish Date: December 14, 2022
Intervention Type: Other, Drug, Biological
Study Phase: Not Applicable
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Recruiting
Publish Date: December 02, 2022
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
Enhancement of Access to and Diversity in Cancer Clinical Trials Through a Financial Reimbursement and Outreach Program
Enrollment Status: Recruiting
Publish Date: August 03, 2022
Intervention Type: Behavioral
An Investigator-sponsored Phase 2 Trial of Afatinib Plus Prednisone for Advanced Squamous Non-small Cell Lung Cancer
Enrollment Status: Recruiting
Publish Date: June 30, 2022
Intervention Type: Drug
Study Drugs: AfatinibPrednisone
Study Phase: Phase 2
The National Myelodysplastic Syndromes Natural History Study
Enrollment Status: Recruiting
Publish Date: April 12, 2022
Intervention Type: Other
A Phase 2 Multi-center Pharmacodynamics Study of TVB-2640 in KRAS Mutant Non-small Cell Lung Carcinomas
Enrollment Status: Recruiting
Publish Date: February 21, 2022
Intervention Type: Drug
Study Drug: TVB-2640
Study Phase: Phase 2
Phase 2 Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors in Refractory ALK Rearranged Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Recruiting
Publish Date: January 30, 2020
Intervention Type: Drug
Study Drug: Brigatinib
Study Phase: Phase 2
An Investigator-sponsored, Phase 1/2 Trial of the Oral XPO1 Inhibitor Selinexor (KPT-330) Monotherapy and in Combination With Docetaxel for Previously Treated, Advanced KRAS Mutant Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Active, not recruiting
Publish Date: November 18, 2022
Intervention Type: Drug
Study Drug: Selinexor
Study Phase: Phase 1/Phase 2
Randomized Study of Erlotinib vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active, not recruiting
Publish Date: October 19, 2022
Intervention Type: Other, Drug
Study Phase: Phase 3
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) - A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active, not recruiting
Publish Date: September 26, 2022
Intervention Type: Biological
Study Drug: Nivolumab
Study Phase: Phase 3
Phase II Concurrent Durvalumab (MEDI4736) and Radiotherapy Followed by Consolidative Durvalumab (MEDI4736) for Stage III Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active, not recruiting
Publish Date: August 19, 2022
Intervention Type: Drug, Radiation
Study Drug: Consolidative Durvalumab
Study Phase: Phase 2
Phase 1 Trial of Dose Escalated BGB324 in Combination With Docetaxel for Previously Treated Advanced Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Active, not recruiting
Publish Date: June 30, 2022
Intervention Type: Drug
Study Drugs: BGB324Docetaxel
Study Phase: Phase 1
Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel After Standard First-Line Induction Chemotherapy in Advanced NSCLC
Enrollment Status: Completed
Publish Date: June 03, 2022
Intervention Type: Drug
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Randomized Controlled Trial (RCT) of Patient Navigation for Lung Cancer Screening in an Urban Safety-Net System
Enrollment Status: Active, not recruiting
Publish Date: April 01, 2022
Intervention Type: Behavioral
Study Phase: Not Applicable
Phase I Trial of Intravenous Fenretinide (4-HPR) Plus Intravenous Safingol for Patients With Relapsed Malignancies
Enrollment Status: Terminated
Publish Date: March 31, 2022
Intervention Type: Drug
Study Drug: Fenretinide (4-HPR) plus Intravenous Safingol
Study Phase: Phase 1
A Multiple Dose, Dose Escalation Trial of AEB1102 (Co-ArgI-PEG) in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: November 05, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
An Open-label, Single-Arm, Phase 2 Study Evaluating the Efficacy, Safety and Pharmacokinetics of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)
Enrollment Status: Completed
Publish Date: July 30, 2021
Intervention Type: Drug
Study Phase: Phase 2
Randomized, Double Blinded Phase III Trial of Cisplatin and Etoposide Plus Thoracic Radiation Therapy Followed By Nivolumab/Placebo For Locally Advanced Non-Small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: June 02, 2021
Intervention Type: Radiation, Other, Drug
Study Phase: Phase 3
A Phase I/II Study of Erlotinib and Romidepsin in Advanced Non-Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: January 20, 2021
Intervention Type: Combination Product
Study Phase: Phase 1
A Phase 2 Study of LY2606368 in Patients With Extensive Stage Disease Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: March 17, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1 Dose Escalation and Pharmacodynamic Study of ARQ 761 (Beta-Lapachone) in Adult Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: March 17, 2020
Intervention Type: Drug
Study Phase: Phase 1
Phase II Study of VS-6063, A Focal Adhesion Kinase (FAK) Inhibitor, in Patients With KRAS Mutant Non-Small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: April 13, 2017
Intervention Type: Drug
Study Phase: Phase 2
A Three-Month, Open-Label, Two Cohort Study to Investigate the Safety and Tolerability of Myfortic in Combination With Neoral (Cyclosporin) or Prograf (Tacrolimus) in Liver Transplant Recipients With GI Intolerance
Enrollment Status: Completed
Publish Date: June 03, 2011
Intervention Type: Drug
A Multicenter, Open-Label Safety and Pharmacokinetics Study of Chimeric Anti-Phosphatidylserine Monoclonal Antibody (Bavituximab) in Patients With Refractory Advanced Solid Tumor Malignancies
Enrollment Status: Completed
Publish Date: March 01, 2011
Intervention Type: Drug
Study Phase: Phase 1
View 17 Less Clinical Trials -
231 Total Publications
Decentralized Clinical Trials in Oncology: Are We Ready for a Virtual-First Paradigm?
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 22, 2022
Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors
JM
Dr. John D. Minna
Hematology Oncology | Oncology
Highly rated in
10
conditions
Hematology Oncology
Oncology

UT Southwestern - Pediatrics

5323 Harry Hines Blvd, 
Dallas, TX 
 0.4 mi

John Minna is a Hematologist Oncology specialist and an Oncologist in Dallas, Texas. Minna has been practicing medicine for over 56 years and is highly rated in 10 conditions, according to our data. His top areas of expertise are Lung Cancer, Lung Adenocarcinoma, Non-Small Cell Lung Cancer (NCSLC), and Small Cell Lung Cancer (SCLC). He is licensed to treat patients in Texas. Minna is currently accepting new patients.

FA
Dr. Farrukh T. Awan
Hematology Oncology | Hematology
Highly rated in
27
conditions
Hematology Oncology
Hematology

University of Texas Southwestern Medical Center

University Hospital Bone Marrow Transplantation/Hematologic Malignancies Clinic

2201 Inwood Rd, 
Dallas, TX 

Farrukh Awan is a Hematologist Oncology specialist and a Hematologist in Dallas, Texas. Awan has been practicing medicine for over 22 years and is highly rated in 27 conditions, according to our data. His top areas of expertise are Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Bone Marrow Transplant, and Bone Marrow Aspiration. He is licensed to treat patients in Georgia, Ohio, and Texas. Awan is currently accepting new patients.

HH
Dr. Hans J. Hammers
Oncology
Highly rated in
9
conditions
Oncology

University of Texas Southwestern Medical Center

University Hospital Medical Oncology Clinic - Genitourinary At Seay Biomedical Building

2201 Inwood Rd, 
Dallas, TX 

Hans Hammers is an Oncologist in Dallas, Texas. Hammers has been practicing medicine for over 24 years and is highly rated in 9 conditions, according to our data. His top areas of expertise are Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, WT1-Related Wilms Tumor Syndromes, Gamma Knife Radiosurgery, and Orchiectomy. He is licensed to treat patients in Texas. Hammers is currently accepting new patients.